SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Ventrus Biosciences, Inc. Receives FDA Written Feedback, Targets NDA Filing for Diltiazem (VEN 307) in Anal Fissures Following Second Phase 3 Study